MTOR and neoplasm: This is evidenced by the synergistic suppression of tumor growth and the effective inhibition of phosphorylated AKT, ERK, and S6 achieved with combined treatment of the TORC1/2 inhibitor AZD8055 and the MEK inhibitor AZD6244, whereas the combination of the PI3K/mTOR inhibitor NVP-BEZ235 with AZD6244 showed limited efficacy [343].